Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Entrada Therapeutics Inc (TRDA)

115 + Investors. Track Smart Money conviction in TRDA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +4
Streak
1Q ▲
Buyers last Q
59%

Smart Money Signals — TRDA

Based on 116 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added TRDA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
116 hedge funds hold TRDA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +6% more funds vs a year ago

fund count last 6Q
+7 new funds entered over the past year (+6% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 59% buying

66 buying46 selling
Last quarter: 66 funds bought or added vs 46 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~19 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 20 → 25 → 17 → 19. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

41% of holders stayed for 2+ years

■ 41% conviction (2yr+) ■ 32% medium ■ 28% new
47 out of 116 hedge funds have held TRDA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +25% but shares only +4% — price-driven

Value
+25%
Shares
+4%
Last quarter: the total dollar value of institutional holdings rose +25%, but actual share count only changed +4%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📊

Peak discovery — momentum slowing

21 → 20 → 25 → 17 → 19 new funds/Q
New funds entering each quarter: 20 → 25 → 17 → 19. TRDA is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 45% veterans vs 33% newcomers

■ 45% veterans ■ 21% 1-2yr ■ 33% new
Entry-cohort mix of 117 holders: 53 (45%) are 2+ year veterans, 25 entered 1–2 years ago, and 39 (33%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 31% AUM from major funds

31% from top-100 AUM funds
41 of 116 holders rank in the top 100 by AUM, accounting for 31% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TRDA

In 2026 Q1, 66 hedge funds were net buyers of TRDA (19 opened a new position, 47 added to an existing one), while 46 reduced or exited (31 trimmed, 15 sold completely) — a 59% buyer ratio, indicating a slight buying edge. 31% of total institutional value in TRDA is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +4 funds (more new holders than closures). Total institutional holders: 116.

Hedge Fund Ownership: TRDA

How many hedge funds hold TRDA — quarterly history vs. share price
Quarterly hedge fund ownership of TRDA vs. share price

Market Analysis: TRDA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TRDA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Entrada Therapeutics Inc (TRDA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TRDA has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 47d ago
TRDA
+1.4%
XLV
+5.5%

TRDA outperformed XLV by -4.1% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 2d ago
TRDA
+0.0%
XLV
+0.0%

Since the filing became public, TRDA outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

14 top-rated funds 0 high-conviction
Consensus
5.1
/ 10
breadth
×
Elite
1.0
/ 10
conviction
Hedge Fund Positioning: TRDA
2026 Q2 Stats Unlock in 3 days 115 + Investors

Track Smart Money conviction in TRDA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 115 112 2.68%
13F Shares 25M 24M 4.19%
Total Value $310M $248M 25.22%
New Positions 18 17 +1
Increased Positions 46 33 +13
Closed Positions 15 18 -3
Reduced Positions 30 43 -13
Total Calls 1 1 -
Total Puts 0 1 -100.0%
PUT/CALL Ratio 0.0 1.0 Bullish

Statistics: TRDA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

115 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TRDA. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 TRDA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 5AM Venture Management, LLC 10.37% 4,056,379 $29.9M
2 Merck & Co., Inc. 2.43% 1,739,768 $12.8M
3 MPM BioImpact LLC 0.56% 1,253,053 $9.2M
4 Nan Fung Group Holdings Ltd 0.27% 49,082 $361K
5 StepStone Group LP 0.26% 761,277 $5.6M
6 Lynx1 Capital Management LP 0.26% 178,606 $1.3M
7 EntryPoint Capital, LLC 0.23% 23,992 $342K
8 Verdad Advisers, LP 0.19% 27,500 $202K
9 TCG Crossover Management, LLC 0.19% 1,060,230 $7.8M
10 Baker BROS. Advisors LP 0.19% 5,072,730 $37.3M
11 Nantahala Capital Management, LLC 0.07% 300,575 $2.2M
12 Odyssean, LLC 0.04% 31,305 $230K
13 Longaeva Partners L.P. 0.03% 195,237 $1.4M
14 Inscription Capital, LLC 0.02% 23,941 $176K
15 China Universal Asset Management Co., Ltd. 0.01% 27,778 $204K
16 Moore Capital Management, LP 0.01% 105,000 $773K
17 XTX Topco Ltd 0.01% 95,337 $702K
18 Jacobs Levy Equity Management, Inc 0.01% 303,459 $2.2M
19 Martingale Asset Management L P 0.01% 38,263 $282K
20 Susquehanna Portfolio Strategies, LLC 0.01% 54,113 $398K
21 Trexquant Investment LP 0.01% 140,143 $1.0M
22 ADAR1 Capital Management, LLC 0.01% 15,500 $114K
23 Y-Intercept (Hong Kong) Ltd 0.01% 34,687 $255K
24 Royce & Associates LP 0.00% 82,902 $610K
25 Cantor Fitzgerald, L. P. 0.00% 60,000 $442K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Entrada Therapeutics Inc (TRDA)

What does the Smart Money Trend signal show for TRDA?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added TRDA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TRDA?

Slight buying edge — 59% buying: Last quarter: 66 funds bought or added vs 46 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for TRDA holders?

Strong quality — 31% AUM from major funds: 41 of 116 holders rank in the top 100 by AUM, accounting for 31% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held TRDA?

41% of holders stayed for 2+ years: 47 out of 116 hedge funds have held TRDA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Entrada Therapeutics Inc (TRDA) following the 2026 Q2 hedge fund 13F filings?

As of today, TRDA has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), TRDA has gained +1.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →